Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Conflict of interest as ethical shorthand: understanding the range and nature of "non-financial conflict of interest" in biomedicine.

Grundy Q, Mayes C, Holloway K, Mazzarello S, Thombs BD, Bero L.

J Clin Epidemiol. 2019 Dec 19;120:1-7. doi: 10.1016/j.jclinepi.2019.12.014. [Epub ahead of print]

PMID:
31866470
2.

RoB-SPEO: A tool for assessing risk of bias in studies estimating the prevalence of exposure to occupational risk factors from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury.

Pega F, Norris SL, Backes C, Bero LA, Descatha A, Gagliardi D, Godderis L, Loney T, Modenese A, Morgan RL, Pachito D, Paulo MBS, Scheepers PTJ, Schlünssen V, Sgargi D, Silbergeld EK, Sørensen K, Sutton P, Tenkate T, Torreão Corrêa da Silva D, Ujita Y, van Deventer E, Woodruff TJ, Mandrioli D.

Environ Int. 2020 Feb;135:105039. doi: 10.1016/j.envint.2019.105039. Epub 2019 Dec 18.

3.

The SSSPIN study-spin in studies of spin: meta-research analysis.

Bero L, Chiu K, Grundy Q.

BMJ. 2019 Dec 18;367:l6202. doi: 10.1136/bmj.l6202.

4.

"Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.

Parker L, Fabbri A, Grundy Q, Mintzes B, Bero L.

BMJ. 2019 Dec 12;367:l6694. doi: 10.1136/bmj.l6694.

PMID:
31831471
5.

Response to Soares et al.

Bero L, Hróbjartsson A, Grundy Q.

Eur J Clin Nutr. 2019 Dec 10. doi: 10.1038/s41430-019-0545-3. [Epub ahead of print] No abstract available.

PMID:
31822820
6.

Cochrane Sustainable Healthcare: evidence for action on too much medicine.

Johansson M, Bero L, Bonfill X, Bruschettini M, Garner S, Glenton C, Harris R, Jørgensen KJ, Levinson W, Lotfi T, Montori V, Meng DM, Schünemann H, Vaz Carneiro A, Woloshin S, Moynihan R.

Cochrane Database Syst Rev. 2019 Dec 6;12:ED000143. doi: 10.1002/14651858.ED000143. No abstract available.

PMID:
31808554
7.

Health promoter, advocate, legitimiser - the many roles of WHO guidelines: a qualitative study.

Wang Z, Grundy Q, Parker L, Bero L.

Health Res Policy Syst. 2019 Dec 5;17(1):96. doi: 10.1186/s12961-019-0489-z.

8.

Pathways to independence: towards producing and using trustworthy evidence.

Moynihan R, Bero L, Hill S, Johansson M, Lexchin J, Macdonald H, Mintzes B, Pearson C, Rodwin MA, Stavdal A, Stegenga J, Thombs BD, Thornton H, Vandvik PO, Wieseler B, Godlee F.

BMJ. 2019 Dec 3;367:l6576. doi: 10.1136/bmj.l6576. No abstract available.

PMID:
31796508
9.

Methodological quality of public health guideline recommendations on vitamin D and calcium : a systematic review protocol.

Dai Z, Kroeger CM, McDonald S, Page MJ, McKenzie JE, Allman-Farinelli M, Raubenheimer D, Bero L.

BMJ Open. 2019 Nov 7;9(11):e031840. doi: 10.1136/bmjopen-2019-031840.

10.

How can the integrity of occupational and environmental health research be maintained in the presence of conflicting interests?

Baur X, Soskolne CL, Bero LA.

Environ Health. 2019 Nov 4;18(1):93. doi: 10.1186/s12940-019-0527-x.

11.

National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism.

Urato AC, Abi-Jaoude E, Abramson J, Alter H, Andrew LB, Antonuccio D, Bero L, Biron P, Boylan LS, Braillon A, Brophy JM, Brownlee S, Cassels A, Cook-Deegan R, Cosgrove L, De Fiore L, Deyo RA, Elshaug A, Farquhar C, Fatovich DM, Fingerman E, Gérvas J, Gøtzsche PC, Gracia R, Heath I, Himmelstein DU, Hoffman JR, Järvinen T, Jureidini J, Kotaska A, Kuehlein T, Lenzer J, Levenstein S, Lexchin J, Mintzes B, Naudet F, Niquette M, Orellana Navarrete LP, Pearson CA, Rail G, Roberts R, Shah N, Sharav V, Siwek J, Topolski S, Tsai AC.

Obstet Gynecol. 2019 Nov;134(5):1115-1117. doi: 10.1097/AOG.0000000000003540. No abstract available.

PMID:
31651818
12.

Policies affecting the supply and access of opioid analgesics: a scoping review protocol.

Chiu K, McDonald S, Legg T, Karanges EA, Bero L.

JBI Database System Rev Implement Rep. 2019 Oct 5. doi: 10.11124/JBISRIR-D-19-00095. [Epub ahead of print]

PMID:
31592835
13.

Commercialization of User Data by Developers of Medicines-Related Apps: a Content Analysis.

Grundy Q, Chiu K, Bero L.

J Gen Intern Med. 2019 Dec;34(12):2833-2841. doi: 10.1007/s11606-019-05214-0.

PMID:
31529374
14.

The IARC Monographs: Updated Procedures for Modern and Transparent Evidence Synthesis in Cancer Hazard Identification.

Samet JM, Chiu WA, Cogliano V, Jinot J, Kriebel D, Lunn RM, Beland FA, Bero L, Browne P, Fritschi L, Kanno J, Lachenmeier DW, Lan Q, Lasfargues G, Le Curieux F, Peters S, Shubat P, Sone H, White MC, Williamson J, Yakubovskaya M, Siemiatycki J, White PA, Guyton KZ, Schubauer-Berigan MK, Hall AL, Grosse Y, Bouvard V, Benbrahim-Tallaa L, El Ghissassi F, Lauby-Secretan B, Armstrong B, Saracci R, Zavadil J, Straif K, Wild CP.

J Natl Cancer Inst. 2020 Jan 1;112(1):30-37. doi: 10.1093/jnci/djz169.

15.

Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study.

Behdarvand B, Karanges EA, Bero L.

BMJ Open. 2019 Aug 20;9(8):e030253. doi: 10.1136/bmjopen-2019-030253.

16.

Response to Acquavella J, conflict of interest: a hazard for epidemiology.

Soskolne CL, Advani S, Sass J, Bero LA, Ruff K.

Ann Epidemiol. 2019 Aug;36:62-63. doi: 10.1016/j.annepidem.2019.07.010. Epub 2019 Jul 16. No abstract available.

PMID:
31401133
17.

Private food safety standards in the global food supply chain: a scoping review protocol.

Trevena H, Reeve B, Bero L, Thow AM.

JBI Database System Rev Implement Rep. 2020 Jan;18(1):97-107. doi: 10.11124/JBISRIR-D-19-00006.

PMID:
31389853
18.

Conflicts of interest between the sugary food and beverage industry and dental research organisations: time for reform.

Kearns CE, Bero LA.

Lancet. 2019 Jul 20;394(10194):194-196. doi: 10.1016/S0140-6736(19)31277-2. No abstract available.

PMID:
31327353
19.

Understanding the Nature and Extent of Pharmaceutical Industry Payments to Nonphysician Clinicians.

Karanges EA, Grundy Q, Bero L.

JAMA Intern Med. 2019 Jun 10. doi: 10.1001/jamainternmed.2019.1371. [Epub ahead of print] No abstract available.

PMID:
31180446
20.

Association of industry ties with outcomes of studies examining the effect of wholegrain foods on cardiovascular disease and mortality: systematic review and meta-analysis.

Chartres N, Fabbri A, McDonald S, Turton J, Allman-Farinelli M, McKenzie J, Bero L.

BMJ Open. 2019 May 19;9(5):e022912. doi: 10.1136/bmjopen-2018-022912.

21.

Making nutrition guidelines fit for purpose.

Bero LA, Norris SL, Lawrence MA.

BMJ. 2019 Apr 16;365:l1579. doi: 10.1136/bmj.l1579. No abstract available.

PMID:
30992263
22.

Commercial interests, transparency, and independence: a call for submissions.

Moynihan R, Macdonald H, Heneghan C, Bero L, Godlee F.

BMJ. 2019 Apr 16;365:l1706. doi: 10.1136/bmj.l1706. No abstract available.

PMID:
30992258
23.

The "Hot Potato" of Mental Health App Regulation: A Critical Case Study of the Australian Policy Arena.

Parker L, Bero L, Gillies D, Raven M, Grundy Q.

Int J Health Policy Manag. 2019 Mar 1;8(3):168-176. doi: 10.15171/ijhpm.2018.117.

24.

Medical donations are not always free: an assessment of compliance of medicine and medical device donations with World Health Organization guidelines (2009-2017).

McDonald S, Fabbri A, Parker L, Williams J, Bero L.

Int Health. 2019 Sep 2;11(5):379-402. doi: 10.1093/inthealth/ihz004.

PMID:
30916303
25.

Data sharing practices of medicines related apps and the mobile ecosystem: traffic, content, and network analysis.

Grundy Q, Chiu K, Held F, Continella A, Bero L, Holz R.

BMJ. 2019 Mar 20;364:l920. doi: 10.1136/bmj.l920.

26.

Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories.

Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E, Bero L.

BMJ Open. 2019 Feb 5;9(2):e025864. doi: 10.1136/bmjopen-2018-025864.

27.

Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.

Parker L, Karanges EA, Bero L.

BMJ Open. 2019 Feb 19;9(2):e024928. doi: 10.1136/bmjopen-2018-024928.

28.

Design characteristics and statistical methods used in interrupted time series studies evaluating public health interventions: protocol for a review.

Turner SL, Karahalios A, Forbes AB, Taljaard M, Grimshaw JM, Cheng AC, Bero L, McKenzie JE.

BMJ Open. 2019 Jan 28;9(1):e024096. doi: 10.1136/bmjopen-2018-024096.

29.

The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures.

Bero L, Chartres N, Diong J, Fabbri A, Ghersi D, Lam J, Lau A, McDonald S, Mintzes B, Sutton P, Turton JL, Woodruff TJ.

Syst Rev. 2018 Dec 21;7(1):242. doi: 10.1186/s13643-018-0915-2.

30.

A review of methods used for hazard identification and risk assessment of environmental hazards.

Chartres N, Bero LA, Norris SL.

Environ Int. 2019 Feb;123:231-239. doi: 10.1016/j.envint.2018.11.060. Epub 2018 Dec 8. Review.

31.

Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors.

Rasmussen K, Bero L, Redberg R, Gøtzsche PC, Lundh A.

BMJ. 2018 Oct 3;363:k3654. doi: 10.1136/bmj.k3654. Erratum in: BMJ. 2018 Oct 11;363:k4298.

32.

The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review.

Fabbri A, Lai A, Grundy Q, Bero LA.

Am J Public Health. 2018 Nov;108(11):e9-e16. doi: 10.2105/AJPH.2018.304677. Epub 2018 Sep 25. Review.

33.

Philip Morris International-funded 'Foundation for a Smoke-Free World': analysing its claims of independence.

van der Eijk Y, Bero LA, Malone RE.

Tob Control. 2019 Nov;28(6):712-718. doi: 10.1136/tobaccocontrol-2018-054278. Epub 2018 Sep 21.

PMID:
30242044
34.

Food industry sponsorship of academic research: investigating commercial bias in the research agenda.

Fabbri A, Holland TJ, Bero LA.

Public Health Nutr. 2018 Dec;21(18):3422-3430. doi: 10.1017/S1368980018002100. Epub 2018 Aug 30.

PMID:
30157979
35.

Industry sponsorship and research outcome: systematic review with meta-analysis.

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L.

Intensive Care Med. 2018 Oct;44(10):1603-1612. doi: 10.1007/s00134-018-5293-7. Epub 2018 Aug 21.

PMID:
30132025
36.

Mental Health Messages in Prominent Mental Health Apps.

Parker L, Bero L, Gillies D, Raven M, Mintzes B, Jureidini J, Grundy Q.

Ann Fam Med. 2018 Jul;16(4):338-342. doi: 10.1370/afm.2260.

37.

Conflicts of Interest in Nutrition Research.

Bero L, Grundy Q.

JAMA. 2018 Jul 3;320(1):93-94. doi: 10.1001/jama.2018.5662. No abstract available.

PMID:
29971390
38.

Interpreting evidence in general practice: Bias and conflicts of interest.

Parker L, Grundy Q, Bero L.

Aust J Gen Pract. 2018 Jun;47(6):337-340. doi: 10.31128/AJGP-12-17-4432.

39.

Ten tips for spotting industry involvement in science policy.

Bero L.

Tob Control. 2019 Jan;28(1):1-2. doi: 10.1136/tobaccocontrol-2018-054386. Epub 2018 Jun 25. No abstract available.

PMID:
29941543
40.

Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality.

de Rezende LFM, Rey-López JP, de Sá TH, Chartres N, Fabbri A, Powell L, Stamatakis E, Bero L.

PLoS Biol. 2018 Jun 18;16(6):e2005761. doi: 10.1371/journal.pbio.2005761. eCollection 2018 Jun.

41.

The advantages and limitations of guideline adaptation frameworks.

Wang Z, Norris SL, Bero L.

Implement Sci. 2018 May 29;13(1):72. doi: 10.1186/s13012-018-0763-4.

42.

Ethical drug marketing criteria for the 21st century.

Parker L, Williams J, Bero L.

BMJ. 2018 Apr 30;361:k1809. doi: 10.1136/bmj.k1809. Review. No abstract available.

PMID:
29712644
43.

Not All Influences on Science Are Conflicts of Interest.

Bero LA, Grundy Q.

Am J Public Health. 2018 May;108(5):632-633. doi: 10.2105/AJPH.2018.304334. No abstract available.

PMID:
29617619
44.

Meta-research matters: Meta-spin cycles, the blindness of bias, and rebuilding trust.

Bero L.

PLoS Biol. 2018 Apr 2;16(4):e2005972. doi: 10.1371/journal.pbio.2005972. eCollection 2018 Apr.

45.

Essential medicines availability is still suboptimal in many countries: a scoping review.

Mahmić-Kaknjo M, Jeličić-Kadić A, Utrobičić A, Chan K, Bero L, Marušić A.

J Clin Epidemiol. 2018 Jun;98:41-52. doi: 10.1016/j.jclinepi.2018.02.006. Epub 2018 Feb 13. Review.

PMID:
29452222
46.

Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study.

Mintzes B, Swandari S, Fabbri A, Grundy Q, Moynihan R, Bero L.

BMJ Open. 2018 Feb 13;8(2):e019027. doi: 10.1136/bmjopen-2017-019027.

47.

An analysis of methods used to synthesize evidence and grade recommendations in food-based dietary guidelines.

Blake P, Durão S, Naude CE, Bero L.

Nutr Rev. 2018 Apr 1;76(4):290-300. doi: 10.1093/nutrit/nux074. Review.

48.

Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores.

Grundy Q, Dunn AG, Bourgeois FT, Coiera E, Bero L.

JAMA. 2018 Jan 23;319(4):408-409. doi: 10.1001/jama.2017.20738. No abstract available.

49.

Improving the Use of Research Evidence in Guideline Development [Internet].

Oxman AD, Schünemann HJ, Fretheim A, Boyd EA, Bero LA, Tan-Torres Edejer T.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2007 Mar.

50.

Getting the systematic review basics right helps clinical practice: 4 common pitfalls for systematic review authors to avoid.

Bero L.

Br J Sports Med. 2019 Jan;53(1):6-8. doi: 10.1136/bjsports-2017-098239. Epub 2017 Dec 7. No abstract available.

PMID:
29217534

Supplemental Content

Loading ...
Support Center